구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel, Infusion of Axicabtagene Ciloleucel) Kite / Gilead·FRα 30 trials |
|---|---|
Overview Program | Infusion of Axicabtagene Ciloleucel |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | Reported |
Clinical Safety signal | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Clinical Selected reported efficacy | ORR 94% |
Clinical Reported ORR | 94% |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03105336 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel, Infusion of Axicabtagene Ciloleucel) Kite / Gilead·FRα 30 trials |
|---|---|
Overview Program | Infusion of Axicabtagene Ciloleucel |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | Reported |
Clinical Safety signal | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Clinical Selected reported efficacy | ORR 94% |
Clinical Reported ORR | 94% |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03105336 |
추천 비교
추천 비교